2016 update of the EULAR recommendations for the management of early arthritis

Annals of the Rheumatic Diseases

Volumn 76, Issue 6, 2017, Pages 948-959

  Combe, Bernard ^a   Landewe, Robert ^b   Daien, Claire I ^a   Hua, Charlotte ^a   Aletaha, Daniel ^c   Álvaro Gracia, Jose María ^d   Bakkers, Margôt ^e   Brodin, Nina ^f,g   Burmester, Gerd R ^h   Codreanu, Catalin ⁱ   Conway, Richard ^j   Dougados, Maxime ^k   Emery, Paul ^l   Ferraccioli, Gianfranco ^m   Fonseca, Joao ^n,o   Raza, Karim ^p,q   Silva Fernández, Lucía ^r   Smolen, Josef S ^c   Skingle, Diana ^e   Szekanecz, Zoltan ^s   Kvien, Tore K ^t   Van Der Helm Van Mil, Annette ^u,v   Van Vollenhoven, Ronald ^w   more..

^a UNIV MONTPELLIER   (France)

^b Zuyderland Medical Centre   (Netherlands)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^e EULAR Standing Committee of People with Arthritis/Rheumatism in Europe (PARE)   (Switzerland)

^f KAROLINSKA INSTITUTE   (Sweden)

^g DANDERYD HOSPITAL   (Sweden)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^j ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^k UNIVERSITÉ PARIS DESCARTES   (France)

^l UNIVERSITY OF LEEDS   (United Kingdom)

^m FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

ⁿ HOSPITAL DE SANTA MARIA   (Portugal)

^o UNIVERSITY OF LISBON   (Portugal)

^p UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^q SANDWELL AND WEST BIRMINGHAM HOSPITALS NHS TRUST   (United Kingdom)

^r Universidad de La Coruña   (Spain)

^s UNIVERSITY OF DEBRECEN   (Hungary)

^t DIAKONHJEMMET HOSPITAL   (Norway)

^u LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^v ERASMUS MEDICAL CENTER   (Netherlands)

^w ACADEMIC MEDICAL CENTER   (Netherlands)

more..

Author keywords

DMARDs (synthetic); Early Rheumatoid Arthritis; Patient perspective; Rheumatoid Arthritis; Treatment

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT;

ARTICLE; COMORBIDITY; DENTAL PROCEDURE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; EVIDENCE BASED PRACTICE; EXERCISE; HEALTH CARE PERSONNEL; HEALTH EDUCATION; HUMAN; HYDROTHERAPY; LIFE EXPECTANCY; MEDICAL INFORMATION; MONITORING; MONOTHERAPY; OCCUPATIONAL THERAPY; PATIENT REFERRAL; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RHEUMATOID ARTHRITIS; RHEUMATOLOGIST; SMOKING CESSATION; WEIGHT CONTROL; ARTHRITIS; KINESIOTHERAPY; LIFESTYLE; PRACTICE GUIDELINE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS; EXERCISE THERAPY; GLUCOCORTICOIDS; HUMANS; LIFE STYLE; OCCUPATIONAL THERAPY;

EID: 85007256365     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-210602     Document Type: Article

References (88)

1. Machado P, Castrejon I, Katchamart W, et al. Multinational evidence-based recommendations on how to investigate and follow-up undifferentiated peripheral inflammatory arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2011;70:15-24.
2. Huizinga TWJ, Machold KP, Breedveld FC, et al. Criteria for early rheumatoid arthritis: from Bayes law revisited to new thoughts on pathogenesis. Arthritis Rheum 2002;46:1155-9.
3. Combe B. Early rheumatoid arthritis: strategies for prevention and management. Best Pract Res Clin Rheumatol 2007;21:27-42.
4. Gaujoux-Viala C, Nam J, Ramiro S, et al. Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: A systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2014;73:510-15.
5. Smolen JS, Aletaha D, Koeller M, et al. New therapies for treatment of rheumatoid arthritis. Lancet 2007;370:1861-74.
6. Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2016;75:499-510.
7. Nam JL, Ramiro S, Gaujoux-Viala C, et al. Efficacy of biological disease-modifying antirheumatic drugs: A systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2014;73:516-28.
8. Avci AB, Feist E, Burmester G-R. Biologicals in rheumatoid arthritis: current and future. RMD Open 2015;1:e000127.
9. Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:34-45.
10. Monti S, Montecucco C, Bugatti S, et al. Rheumatoid arthritis treatment: The earlier the better to prevent joint damage. RMD Open 2015;1(Suppl 1):e000057.
11. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 2016;75:3-15.
12. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
13. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
14. van der Heijde D, Aletaha D, Carmona L, et al. 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Ann Rheum Dis 2015;74:8-13.
15. Hua C, Daien CI, Combe B. Diagnosis, prognosis and classification of early arthritis: results of a systematic literature informing the 2016 update of the EULAR recommendations for the management of early arthritis. RMD Open.
16. Daïen CI, Hua C, Combe B, et al. Pharmacologic and non-pharmacologic therapies in early arthritis: results of a systematic literature informing the 2016 update of the EULAR recommendations for the management of early arthritis. RMD Open 2016.
17. OCEBM Levels of Evidence. CEBM. 2016 (cited 3 May 2016). http://www.cebm.net/ocebm-levels-of-evidence/
18. Bykerk V, Emery P. Delay in receiving rheumatology care leads to long-Term harm. Arthritis Rheum 2010;62:3519-21.
19. van der Linden MPM, le Cessie S, Raza K, et al. Long-Term impact of delay in assessment of patients with early arthritis. Arthritis Rheum 2010;62:3537-46.
20. Feldman DE, Bernatsky S, Houde M, et al. Early consultation with a rheumatologist for RA: does it reduce subsequent use of orthopaedic surgery? Rheumatology 2013;52:452-9.
21. Stoffer MA, Smolen JS, Woolf A, et al. Development of patient-centred standards of care for rheumatoid arthritis in Europe: The eumusc.net project. Ann Rheum Dis 2014;73:902-5.
22. Emery P, Breedveld FC, Dougados M, et al. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 2002;61:290-7.
23. Colebatch AN, Edwards CJ, Østergaard M, et al. EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis 2013;72:804-14.
24. Duer-Jensen A, Hørslev-Petersen K, Hetland ML, et al. Bone edema on magnetic resonance imaging is an independent predictor of rheumatoid arthritis development in patients with early undifferentiated arthritis. Arthritis Rheum 2011;63: 2192-202.
25. Nieuwenhuis WP, Krabben A, Stomp W, et al. Evaluation of magnetic resonance imaging-detected tenosynovitis in the hand and wrist in early arthritis. Arthritis Rheumatol 2015;67:869-76.
26. Mangnus L, Schoones JW, van der Helm-van Mil AHM. What is the prevalence of MRI-detected inflammation and erosions in small joints in the general population? A collation and analysis of published data. RMD Open 2015;1:e000005.
27. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8.
28. Funovits J, Aletaha D, Bykerk V, et al. The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: methodological report phase I. Ann Rheum Dis 2010;69:1589-95.
29. Mouterde G, Lukas C, Logeart I, et al. Predictors of radiographic progression in the ESPOIR cohort: The season of first symptoms may influence the short-Term outcome in early arthritis. Ann Rheum Dis 2011;70:1251-6.
30. van den Broek M, Dirven L, Klarenbeek NB, et al. The association of treatment response and joint damage with ACPA-status in recent-onset RA: A subanalysis of the 8-year follow-up of the BeSt study. Ann Rheum Dis 2012;71:245-8.
31. Hetland ML, Stengaard-Pedersen K, Junker P, et al. Radiographic progression and remission rates in early rheumatoid arthritis-MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial. Ann Rheum Dis 2010;69:1789-95.
32. Degboé Y, Constantin A, Nigon D, et al. Predictive value of autoantibodies from anti-CCP2, anti-MCV and anti-human citrullinated fibrinogen tests, in early rheumatoid arthritis patients with rapid radiographic progression at 1 year: results from the ESPOIR cohort. RMD Open 2015;1:e000180.
33. Akdemir G, Verheul MK, Heimans L, et al. Predictive factors of radiological progression after 2 years of remission-steered treatment in early arthritis patients: A post hoc analysis of the IMPROVED study. RMD Open 2016;2:e000172.
34. van der Heijde D, van der Helm-van Mil AHM, Aletaha D, et al. EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria. Ann Rheum Dis 2013;72:479-81.
35. Rezaei H, Torp-Pedersen S, af Klint E, et al. Diagnostic utility of musculoskeletal ultrasound in patients with suspected arthritis-A probabilistic approach. Arthritis Res Ther 2014;16:448.
36. Sahbudin I, Pickup L, Cader Z, et al. OP0015 ultrasound-defined tenosynovitis is a strong predictor of early rheumatoid arthritis. Ann Rheum Dis 2015;74(Suppl 2):69-70.
37. Bosello S, Fedele AL, Peluso G, et al. Very early rheumatoid arthritis is the major predictor of major outcomes: clinical ACR remission and radiographic non-progression. Ann Rheum Dis 2011;70:1292-5.
38. Gremese E, Salaffi F, Bosello SL, et al. Very early rheumatoid arthritis as a predictor of remission: A multicentre real life prospective study. Ann Rheum Dis 2013;72:858-62.
39. Lukas C, Combe B, Ravaud P, et al. Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: data from the Étude et Suivi des polyarthrites indifférenciées récentes (study and follow-up of early undifferentiated polyarthritis). Arthritis Rheum 2011;63:1804-11.
40. Söderlin MK, Bergman S, BARFOT Study Group. Absent "Window of Opportunity" in smokers with short disease duration. Data from BARFOT, a multicenter study of early rheumatoid arthritis. J Rheumatol 2011;38:2160-8.
41. van Nies JAB, Tsonaka R, Gaujoux-Viala C, et al. Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts. Ann Rheum Dis 2015;74:806-12.
42. Singh JA, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2016;68:1-26.
43. Ramiro S, Gaujoux-Viala C, Nam JL, et al. Safety of synthetic and biological DMARDs: A systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2014;73:529-35.
44. Ramiro S, Smolen JS, Landewé R, et al. Pharmacological treatment of psoriatic arthritis: A systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2016;75:490-8.
45. Visser K, Katchamart W, Loza E, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009;68:1086-93.
46. Verschueren P, De Cock D, Corluy L, et al. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-To-high-dose glucocorticoid bridging in early rheumatoid arthritis after weeks of treatment: The CareRA trial. Ann Rheum Dis 2015;74:27-34.
47. den Uyl D, ter Wee M, Boers M, et al. A non-inferiority trial of an attenuated combination strategy (COBRA-light) compared to the original COBRA strategy: clinical results after 26 weeks. Ann Rheum Dis 2014;73:1071-8.
48. de Jong PH, Hazes JM, Han HK, et al. Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial. Ann Rheum Dis 2014;73:1331-9.
49. Moreland LW, ODell JR, Paulus HE, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum 2012;64:2824-35.
50. Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 2014;370:2377-86.
51. Fleischmann R, Schiff M, van der Heijde D. Baricitinib, Methotrexate, or Combination in Patients with Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment. Arthritis Rheumatol 2016 Oct 9. doi:10. 1002/art.39953.
52. Katz SJ, Russell AS. Re-evaluation of antimalarials in treating rheumatic diseases: re-Appreciation and insights into new mechanisms of action. Curr Opin Rheumatol 2011;23:278-81.
53. Verschueren P, De Cock D, Corluy L, et al. Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial. Arthritis Res Ther 2015;17:97.
54. Seegobin SD, Ma MHY, Dahanayake C, et al. ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial. Arthritis Res Ther 2014;16:R13.
55. Dixon WG, Abrahamowicz M, Beauchamp M-E, et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: A nested case-control analysis. Ann Rheum Dis 2012;71:1128-33.
56. del Rincón I, Battafarano DF, Restrepo JF, et al. Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheumatol 2014;66:264-72.
57. Listing J, Kekow J, Manger B, et al. Mortality in rheumatoid arthritis: The impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab. Ann Rheum Dis 2015;74:415-21.
58. Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: A systematic review and meta-Analysis. Ann Rheum Dis 2015;74: 480-9.
59. Ajeganova S, Svensson B, Hafström I. Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial. BMJ Open 2014;4:e004259.
60. de Hair M. Long-Term Adverse Events after Daily Concomitant Treatment with 10mg Prednisone in the 2-Year Computer Assisted Management in Early Rheumatoid Arthritis Trial-II. ACR Meeting Abstracts [cited 10 May 2016].
61. Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2014;73:6-16.
62. Combe B, Logeart I, Belkacemi MC, et al. Comparison of the long-Term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort. Ann Rheum Dis 2015;74:724-9.
63. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404-13.
64. Ruyssen-Witrand A, Guernec G, Nigon D, et al. Aiming for SDAI remission versus low disease activity at 1 year after inclusion in ESPOIR cohort is associated with better 3-year structural outcomes. Ann Rheum Dis 2015;74:1676-83.
65. Radner H, Smolen JS, Aletaha D. Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs. Arthritis Res Ther 2014;16: R56.
66. Dale J, Stirling A, Zhang R, et al. Targeting ultrasound remission in early rheumatoid arthritis: The results of the TaSER study, a randomised clinical trial. Ann Rheum Dis 2016;75:1043-50.
67. Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): A UK multicentre, open-label, randomised controlled trial. Lancet 2015;386:2489-98.
68. Klarenbeek NB, Göler-Yöksel M, van der Heijde DMFM, et al. Clinical synovitis in a particular joint is associated with progression of erosions and joint space narrowing in that same joint, but not in patients initially treated with infliximab. Ann Rheum Dis 2010;69:2107-13.
69. Gärtner M, Sigmund IK, Alasti F, et al. Clinical joint inactivity predicts structural stability in patients with established rheumatoid arthritis. RMD Open 2016;2: e000241.
70. Akdemir G, Markusse IM, Dirven L, et al. Effectiveness of four dynamic treatment strategies in patients with anticitrullinated protein antibody-negative rheumatoid arthritis: A randomised trial. RMD Open 2016;2:e000143.
71. van Steenbergen HW, Tsonaka R, Huizinga TWJ, et al. Fatigue in rheumatoid arthritis; a persistent problem: A large longitudinal study. RMD Open 2015;1: e000041.
72. Gossec L, Dougados M, Dixon W. Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis. RMD Open 2015;1:e000019.
73. Verhagen AP, Bierma-Zeinstra SM, Boers M, et al. Balneotherapy (or spa therapy) for rheumatoid arthritis. An abridged version of Cochrane Systematic Review. Eur J Phys Rehabil Med 2015;51:833-47.
74. Hurkmans E, van der Giesen FJ, Vliet Vlieland TP, et al. Dynamic exercise programs (aerobic capacity and/or muscle strength training) in patients with rheumatoid arthritis. Cochrane Database Syst Rev 2009;(4):CD006853.
75. Ekelman BA, Hooker L, Davis A, et al. Occupational therapy interventions for adults with rheumatoid arthritis: An appraisal of the evidence. Occup Ther Health Care 2014;28:347-61.
76. Dougados M, Soubrier M, Antunez A, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis 2014;73:62-8.
77. Baillet A, Gossec L, Carmona L, et al. Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: A EULAR initiative. Ann Rheum Dis 2016;75:965-73.
78. Peters MJL, Symmons DPM, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:325-31.
79. Gherghe AM, Dougados M, Combe B, et al. Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohorts. RMD Open 2015;1: e000128.
80. Daïen CI, Sellam J. Obesity and inflammatory arthritis: impact on occurrence, disease characteristics and therapeutic response. RMD Open 2015;1:e000012.
81. Bacconnier L, Rincheval N, Flipo R-M, et al. Psychological distress over time in early rheumatoid arthritis: results from a longitudinal study in an early arthritis cohort. Rheumatology 2015;54:520-7.
82. Radner H, Yoshida K, Mjaavatten MD, et al. Development of a multimorbidity index: impact on quality of life using a rheumatoid arthritis cohort. Semin Arthritis Rheum 2015;45:167-73.
83. Sparks JA, Karlson EW. The roles of cigarette smoking and the lung in the transitions between phases of preclinical rheumatoid arthritis. Curr Rheumatol Rep 2016;18:15.
84. Poddubnyy D, Haibel H, Listing J, et al. Cigarette smoking has a dose-dependent impact on progression of structural damage in the spine in patients with axial spondyloarthritis: results from the German SPondyloarthritis Inception Cohort (GESPIC). Ann Rheum Dis 2013;72:1430-2.
85. Vesperini V, Lukas C, Fautrel B, et al. Association of tobacco exposure and reduction of radiographic progression in early rheumatoid arthritis: results from a French multicenter cohort. Arthritis Care Res 2013;65:1899-906.
86. Fuggle NR, Smith TO, Kaul A, et al. Hand to mouth: A systematic review and meta-Analysis of the association between rheumatoid arthritis and periodontitis. Front Immunol 2016;7:80.
87. Hua C, Morel J, Ardouin E, et al. Reasons for non-vaccination in French rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford) 2015;54:748-50.
88. Zangi HA, Ndosi M, Adams J, et al. EULAR recommendations for patient education for people with inflammatory arthritis. Ann Rheum Dis 2015;74:954-62.